Ozden Rabia Gurses 4
4 · Adverum Biotechnologies, Inc. · Filed Jun 20, 2025
Insider Transaction Report
Form 4
Ozden Rabia Gurses
Chief Medical Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−8,000→ 0 totalExercise: $13.50Exp: 2032-03-16→ Common Stock (8,000 underlying) - Award
Stock Option (Right to Buy)
2025-06-17+8,000→ 8,000 totalExercise: $10.14Exp: 2032-03-16→ Common Stock (8,000 underlying) - Award
Stock Option (Right to Buy)
2025-06-17+4,000→ 4,000 totalExercise: $10.14Exp: 2033-06-08→ Common Stock (4,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-06-17−4,000→ 0 totalExercise: $15.60Exp: 2033-06-08→ Common Stock (4,000 underlying)
Footnotes (3)
- [F1]Effective March 21, 2024, the Issuer effected a reverse stock split (the "Reverse Split") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten.
- [F2]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on March 17, 2022 and is fully vested.
- [F3]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 9, 2023 and is fully vested.